Solutions

Therapeutic Areas

Immune-mediated

Examples

Inflammatory Bowel Disease, Atopic Dermatitis, Rheumatoid Arthritis, Asthma

Immuno-oncology

Examples

Non-small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma

Fibrosis

Examples

Non-alcoholic steatohepatitis, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis

Discovery

Standard of Care (SOC) MoA

Profile your target across disease models, and predict how it interacts with cells, pathways, and successful treatments.

Target Profiling

Build on an ever-growing and ever-updating database to prioritize your targets within any disease model.

Disease Subtypes

Identify populations to most benefit from your drug across disease subtypes and stages, or across patient populations.

Early Development

Indication Assignment

Predict the disease where your drug will be most successful and understand the connection between drug MoA and disease mechanisms.

Comparison to SOC

Compare the activity of existing or potential drugs – all in the context of drug residual disease activity and resistance mechanisms.

clinical development

Competitive Analysis

Compare response sub-groups of multiple drugs. Map clinical relevance based on drug and disease mechanisms.

Indication Expansion

Expand drug development to additional diseases and find out where your drug will be most relevant to disease mechanisms.

Combination Strategy

Understand combination benefits with existing or potential drugs. All in the context of response mechanisms, drug residual disease activity and resistance mechanisms.

Drug MoA

Augment your data with CytoReason’s models to overlay the drug effect on disease mechanisms.

Patient Stratification

Predict patients with best response, and link disease and drug mechanisms to clinical outcomes for better trial design.

Discovery

Standard of Care (SOC) MoA

Profile your target across disease models, and predict how it interacts with cells, pathways, and successful treatments.

Target Profiling

Build on an ever-growing and ever-updating database to prioritize your targets within any disease model.

Disease Subtypes

Identify populations to most benefit from your drug across disease subtypes and stages, or across patient populations.

Early Development

Standard of Care (SOC) MoA

Profile your target across disease models, and predict how it interacts with cells, pathways, and successful treatments.

Target Profiling

Build on an ever-growing and ever-updating database to prioritize your targets within any disease model.

Disease Subtypes

Identify populations to most benefit from your drug across disease subtypes and stages, or across patient populations.

clinical development

Standard of Care (SOC) MoA

Profile your target across disease models, and predict how it interacts with cells, pathways, and successful treatments.

Target Profiling

Build on an ever-growing and ever-updating database to prioritize your targets within any disease model.

Disease Subtypes

Identify populations to most benefit from your drug across disease subtypes and stages, or across patient populations.

The Power of One

One universe linking mechanisms across diseases, treatments and patient groups.

One language across all your drug programs

One space to connect decisions to the underlying science

One platform with solutions for all stakeholders

Solutions

Therapeutic Areas

Immune-mediated

Immuno-oncology

Fibrosis

Discovery

Standard of Care (SOC) MoA

Target Profiling

Disease Subtypes

Early Development

Indication Assignment

Comparison to SOC

clinical development

Competitive Analysis

Indication Expansion

Combination Strategy

Drug MoA

Patient Stratification

Discovery

Standard of Care (SOC) MoA

Target Profiling

Disease Subtypes

Early Development

Standard of Care (SOC) MoA

Target Profiling

Disease Subtypes

clinical development

Standard of Care (SOC) MoA

Target Profiling

Disease Subtypes

The Power of One

Bring your data to life